Identifying proteomic biomarkers to predict the course of early RA
| Reference number | |
| Coordinator | Lipum AB |
| Funding from Vinnova | SEK 2 327 101 |
| Project duration | April 2024 - March 2026 |
| Status | Completed |
| Venture | Swelife - Samverkansprojekt för bättre hälsa |
| Call | Swelife - Collaborative projects for better health autumn 2023 |
Important results from the project
The project has largely achieved its objectives. We have shown that levels of the protein BSSL are elevated in the blood of patients with early (new-onset) RA and are associated with several measures of disease severity. Additional biomarkers that correlate with BSSL have been identified. These findings support BSSL as a potential new therapeutic target. The project has also advanced analytical methods and strengthened collaborations between industry and academia.
Expected long term effects
The project is expected to contribute to the development of biomarkers for earlier diagnosis and improved monitoring of RA, enabling safer and more personalized treatment. The results strengthen the understanding of BSSL as a therapeutic target and may support the development of new therapies, such as SOL-116. The developed method for analyzing BSSL in blood has also strengthened the company’s internal capabilities and created a foundation for continued research, collaboration, and innovation.
Approach and implementation
The project was largely carried out as planned, with relevant activities for biomarker analysis and method development, including analysis of BSSL in clinical samples and complementary proteomics studies. An initial delay at project start required adjustments to the timeline, which was subsequently maintained. Collaboration with KI and LiU worked very well and was further strengthened during the project. The project generated high-quality data.